{"id":33730,"date":"2024-04-24T14:14:48","date_gmt":"2024-04-24T12:14:48","guid":{"rendered":"https:\/\/www.idisantiago.es\/diversa-biotechnologies-has-concluded-its-capital-expansion-with-semola-tech-ventures-sl-volsunga-sl-janus-projects-sl-and-unirisco\/"},"modified":"2024-04-24T14:21:53","modified_gmt":"2024-04-24T12:21:53","slug":"diversa-biotechnologies-has-concluded-its-capital-expansion-with-semola-tech-ventures-sl-volsunga-sl-janus-projects-sl-and-unirisco","status":"publish","type":"post","link":"https:\/\/www.idisantiago.es\/en\/diversa-biotechnologies-has-concluded-its-capital-expansion-with-semola-tech-ventures-sl-volsunga-sl-janus-projects-sl-and-unirisco\/","title":{"rendered":"DIVERSA Biotechnologies has concluded its capital expansion with S\u00e9mola Tech Ventures SL, Volsunga SL, Janus Projects SL, and UNIRISCO."},"content":{"rendered":"
\n
\n
\n
\n
\n

Santiago de Compostela, April 24, 2024.- <\/strong>DIVERSA Technologies SL, a company aiming to make an impact across the entire value chain in the field of biotechnology and nanomedicine, closed its capital expansion. Their focus is on driving the development of innovative drugs to address unmet medical needs. The capital infusion was made possible by UNIRISCO,\u00a0S\u00e9mola Tech Ventures SL,\u00a0Volsunga SL, and\u00a0Janus Projects, SL. Founded on January 17, 2022, after over a decade of research in nanomedicine applied to healthcare, led by Dr. Mar\u00eda de la Fuente, the company emerged as a biotechnological spin-off from the\u00a0Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS)\u00a0and the\u00a0Servizo Galego de Sa\u00fade (SERGAS). Their mission is to impact the development of innovative therapies through the application of nanotechnology, ultimately enhancing people\u2019s quality of life through precision medicine.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n

DIVERSA Technologies, a company born with the mission of enhancing people\u2019s lives and boosting Galicia\u2019s socio-economic fabric, achieves this by creating qualified employment and fostering a collaborative model with local and international research centers and businesses. DIVERSA boasts a patented platform of lipid-based nanosystems, designed for encapsulating and delivering various types of therapeutic molecules to their intended sites of action. These include messenger RNA (mRNA), proteins, therapeutic peptides, and even drugs with solubility challenges. The DIVERSA technology enhances the stability of these encapsulated molecules and helps them overcome biological barriers that might otherwise limit their therapeutic impact. Notably, DIVERSA\u2019s nanosystems have demonstrated their potential across different indications. As a result of their investment in research, the company is making strides in the development of nanomedicines for oncology and rare pediatric diseases.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

\n
\n
\n

These advancements are possible thanks to DIVERSA\u2019s collaborative model, which involves leading research centers and groups focused on these conditions. Additionally, DIVERSA makes its technology available to third parties in pursuit of a \u201cbutterfly effect\u201d that leads to the development of innovative nanomedicines for various indications. To achieve this, DIVERSA proposes establishing agreements with biotechnology and pharmaceutical companies that possess molecules with high therapeutic potential but require an effective formulation. The formulation is based on DIVERSA\u2019s lipid-based nanosystems, enabling their practical application. Furthermore, DIVERSA offers this technology to researchers working in the early stages of drug development. This accessibility is made possible by selling the technology in a \u201cpackaged\u201d format, which can be easily formulated with molecules of interest for testing in their study models. In this way, DIVERSA aims to make a significant impact across multiple avenues and contribute to therapeutic advancements for different diseases.<\/p>\n<\/div>\n

\n
\n
\n
\n

In addition to its business model, DIVERSA also aims to have a positive social and economic impact. Through its research and development activities, as well as collaborations with other companies and institutions, the company creates skilled employment and fosters innovation in the healthcare sector. These strategic partnerships allow for the establishment of a support network that drives the company\u2019s growth and success, contributing to the economic and technological development of Galicia.<\/p>\n

With the closing of this round, the focus is on expanding the business model and enhancing the company\u2019s international presence.<\/p>\n<\/div>\n

Main products or services provided:<\/strong><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n

DIVERSA Technologies S.L. is much more than a biotechnology company. It is an entity committed to innovation, scientific excellence, and the well-being of people. Through its nanotechnology platform and focus on research, development, and commercialization of advanced therapies, the company aims to leave a lasting impact on the healthcare industry and society at large.<\/p>\n

\n
\n
\n

DIVERSA Technologies S.L. not only prioritizes innovation and scientific excellence but also provides revolutionary and highly versatile technology. This technology is used to develop innovative medicines through its R&D efforts or collaborations with the biotechnology and pharmaceutical sectors, as well as research centers. Cutting-edge nanotechnology opens up new avenues for possibilities and business opportunities, adapting to the changing demands and therapeutic needs emerging in the healthcare field.<\/p>\n<\/div>\n

<\/div>\n<\/div>\n
<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The spin-off of the Instituto de Investigaci\u00f3n Sanitaria de Santiago de Compostela (IDIS) and SERGAS, specialized in nanomedicine, aims to have an impact on the development of innovative drugs, specifically in the areas of oncology and rare diseases, but also in many others due to its collaborative business model.<\/p>\n","protected":false},"author":12,"featured_media":33715,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[176,493,522,530],"tags":[],"class_list":["post-33730","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","category-carrusel-de-portada-en","category-carrusel-en-ingles-en","category-carrusel-en-galego-en"],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/posts\/33730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/comments?post=33730"}],"version-history":[{"count":2,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/posts\/33730\/revisions"}],"predecessor-version":[{"id":33732,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/posts\/33730\/revisions\/33732"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/media\/33715"}],"wp:attachment":[{"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/media?parent=33730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/categories?post=33730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.idisantiago.es\/en\/wp-json\/wp\/v2\/tags?post=33730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}